<DOC>
	<DOCNO>NCT00151229</DOCNO>
	<brief_summary>The aim study compare incidence cardiovascular event two target systolic blood pressure level , 140 mmHg 150 mmHg treatment valsartan elderly isolate systolic hypertensive patient Japan .</brief_summary>
	<brief_title>Valsartan Elderly Isolated Systolic Hypertension Study</brief_title>
	<detailed_description>Although antihypertensive therapy proven reduce cardiovascular morbidity mortality , unclear much blood pressure decrease elderly patient hypertension . The Valsartan Elderly Isolated Systolic Hypertension ( VALISH ) study multicenter parallel-group study compare incidence cardiovascular event two target systolic blood pressure level , 140 mmHg 150 mmHg , treatment valsartan , angiotensin II receptor blocker , initial antihypertensive drug elderly patient isolate systolic hypertension . The number patient recruit 3,000 duration follow-up least 2 year . This 3,000-patient trial design two-sided Î± level 0.05 80 % power detect difference incidence cardiovascular event target blood pressure level base estimation cardiovascular event ratio 21.5/1,000 patient-years 29.1/1,000 patient-years two blood pressure level . The VALISH study , large-scale investigator-initiated trial Japan , determine whether age consider set target blood pressure treatment isolate systolic hypertension elderly patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Outpatients age 70 year less 85 year , regardless sex . Patients stable seat systolic blood pressure 160 mmHg diastolic blood pressure le 90 mmHg two visit within 2 4 week . Previously untreated patient patient therapy convert valsartan . Patients secondary hypertension malignant hypertension . Patients seat systolic blood pressure 200 mmHg . Patients seat diastolic blood pressure 90 mmHg . Patients history cerebrovascular disorder myocardial infarction within 6 month prior enrolment study . Patients underwent coronary arterioplasty within 6 month prior enrolment study patient undergo coronary arterioplasty within 6 month entry . Patients severe heart failure ( NYHA functional classification III IV ) . Patients severe aortic stenosis valvular disease . Patients atrial fibrillation , atrial flutter , serious arrhythmia . Patients renal dysfunction serum creatinine level 2 mg/dL . Patients serious liver dysfunction . Patients history hypersensitivity valsartan . Other patient judge inappropriate study investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>isolate systolic hypertension</keyword>
	<keyword>valsartan</keyword>
	<keyword>target blood pressure</keyword>
</DOC>